Transcranial direct current stimulation (tDCS) for treatment of major depression during pregnancy: Study protocol for a pilot randomized controlled trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Vigod, Simone ^a,b   Dennis, Cindy Lee ^a,b   Daskalakis, Zafiris ^b,c   Murphy, Kellie ^b,d   Ray, Joel ^b,e   Oberlander, Tim ^f   Somerton, Sarah ^a   Hussain Shamsy, Neesha ^a   Blumberger, Daniel ^b,c  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Depression; Pregnancy; Transcranial direct brain stimulation (tDCS); Women

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; DISEASE SEVERITY; DSM-5; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR DEPRESSION; MULTICENTER STUDY (TOPIC); PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSCRANIAL DIRECT CURRENT STIMULATION; ADVERSE EFFECTS; CANADA; CLINICAL PROTOCOL; CONTROLLED STUDY; DEPRESSIVE DISORDER, MAJOR; FEASIBILITY STUDY; METHODOLOGY; PILOT STUDY; PREGNANCY COMPLICATIONS; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

CLINICAL PROTOCOLS; DEPRESSIVE DISORDER, MAJOR; FEASIBILITY STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; ONTARIO; PILOT PROJECTS; PREGNANCY; PREGNANCY COMPLICATIONS; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRANSCRANIAL DIRECT CURRENT STIMULATION; TREATMENT OUTCOME;

EID: 84908141742     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-366     Document Type: Article

References (63)

1. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004, 103(4):698-709. 10.1097/01.AOG.0000116689.75396.5f, 15051562.
2. Michaud CM, Murray CJ, Bloom BR. Burden of disease - implications for future research. JAMA 2001, 285(5):535-539. 10.1001/jama.285.5.535, 11176854.
3. Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF, Perel JM, Jones-Ivy S, Bodnar LM, Singer LT. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009, 166(5):557-566. 10.1176/appi.ajp.2008.08081170, 19289451.
4. Marcus SM. Depression during pregnancy: rates, risks and consequences - Motherisk update 2008. Can J Clin Pharmacol 2009, 16(1):e15-e22.
5. Canadian Psychiatric Association; Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001, 46(Suppl 1):1S-91S. Canadian Psychiatric Association; Canadian Network for Mood and Anxiety Treatments (CANMAT).
6. Thase ME, Larsen KG, Kennedy SH. Assessing the 'true' effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model. Br J Psychiatry 2011, 199(6):501-507. 10.1192/bjp.bp.111.093336, 22130749.
7. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006, 354(6):579-587. 10.1056/NEJMoa052744, 16467545.
8. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, Walker M. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006, 194(4):961-966. 10.1016/j.ajog.2006.02.019, 16580283.
9. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, Hoyme HE. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003, 142(4):402-408. 10.1067/mpd.2003.139, 12712058.
10. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996, 335(14):1010-1015. 10.1056/NEJM199610033351402, 8793924.
11. Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000, 48(10):996-1000. 10.1016/S0006-3223(00)00877-5, 11082474.
12. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002, 156(11):1129-1132. 10.1001/archpedi.156.11.1129, 12413342.
13. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999, 55(7):503-508. 10.1007/s002280050664, 10501819.
14. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-Schechman AK, Cook L, Brochu J, Rieder M, Koren G. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998, 279(8):609-610. 10.1001/jama.279.8.609, 9486756.
15. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003, 60(7):720-726. 10.1001/archpsyc.60.7.720, 12860776.
16. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006, 160(2):173-176. 10.1001/archpedi.160.2.173, 16461873.
17. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001, 90(3):288-291. 10.1080/080352501300067596, 11332169.
18. Oberlander TF, Eckstein Grunau R, Fitzgerald C, Ellwood AL, Misri S, Rurak D, Riggs KW. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 2002, 51(4):443-453. 10.1203/00006450-200204000-00008, 11919328.
19. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C, Gardner A, Horn M, Koren G. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993, 269(17):2246-2248. 10.1001/jama.1993.03500170076037, 8474204.
20. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002, 159(12):2055-2061. 10.1176/appi.ajp.159.12.2055, 12450956.
21. Stiskal JA, Kulin N, Koren G, Ho T, Ito S. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed 2001, 84(2):F134-F135. 10.1136/fn.84.2.F134, 1721229, 11207233.
22. Mulder EJ, Ververs FF, de Heus R, Visser GH. Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus. Neuropsychopharmacology 2011, 36(10):1961-1971. 10.1038/npp.2011.67, 3158314, 21525859.
23. Fitzgerald PB, Brown TL, Marston NA, Daskalakis ZJ, De Castella A, Kulkarni J. Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 2003, 60(10):1002-1008.
24. George MS, Ketter TA, Post RM. Prefrontal cortex dysfunction in clinical depression. Depression 1994, 2(2):59-72.
25. Speer AM, Kimbrell TA, Wassermann EM, Repella JD, Willis MW, Herscovitch P, Post RM. Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients. Biol Psychiatry 2000, 48(12):1133-1141. 10.1016/S0006-3223(00)01065-9, 11137053.
26. Ardolino G, Bossi B, Barbieri S, Priori A. Non-synaptic mechanisms underlie the after-effects of cathodal transcutaneous direct current stimulation of the human brain. J Physiol 2005, 568(2):653-663. 10.1113/jphysiol.2005.088310, 1474743, 16037080.
27. Miranda PC, Lomarev M, Hallett M. Modeling the current distribution during transcranial direct current stimulation. Clin Neurophysiol 2006, 117(7):1623-1629. 10.1016/j.clinph.2006.04.009, 16762592.
28. Merzagora AC, Foffani G, Panyavin I, Mordillo-Mateos L, Aguilar J, Onaral B, Oliviero A. Prefrontal hemodynamic changes produced by anodal direct current stimulation. Neuroimage 2010, 49(3):2304-2310. 10.1016/j.neuroimage.2009.10.044, 19853048.
29. Kalu UG, Sexton CE, Loo CK, Ebmeier KP. Transcranial direct current stimulation in the treatment of major depression: a meta-analysis. Psychol Med 2012, 42(9):1791-1800. 10.1017/S0033291711003059, 22236735.
30. Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P. Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. Br J Psychiatry 2012, 200(1):52-59. 10.1192/bjp.bp.111.097634, 22215866.
31. Boggio PS, Castro LO, Savagim EA, Braite R, Cruz VC, Rocha RR, Rigonatti SP, Silva MT, Fregni F. Enhancement of non-dominant hand motor function by anodal transcranial direct current stimulation. Neurosci Lett 2006, 404(1-2):232-236.
32. Fregni F, Boggio PS, Lima MC, Ferreira MJ, Wagner T, Rigonatti SP, Castro AW, Souza DR, Riberto M, Freedman SD, Nitsche MA, Pascual-Leone A. A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury. Pain 2006, 122(1-2):197-209.
33. Fregni F, Boggio PS, Mansur CG, Wagner T, Ferreira MJ, Lima MC, Rigonatti SP, Marcolin MA, Freedman SD, Nitsche MA, Pascual-Leone A. Transcranial direct current stimulation of the unaffected hemisphere in stroke patients. Neuroreport 2005, 16(14):1551-1555. 10.1097/01.wnr.0000177010.44602.5e, 16148743.
34. Fregni F, Boggio PS, Nitsche M, Bermpohl F, Antal A, Feredoes E, Marcolin MA, Rigonatti SP, Silva MT, Paulus W, Pascual-Leone A. Anodal transcranial direct current stimulation of prefrontal cortex enhances working memory. Exp Brain Res 2005, 166(1):23-30. 10.1007/s00221-005-2334-6, 15999258.
35. Fregni F, Boggio PS, Nitsche MA, Marcolin MA, Rigonatti SP, Pascual-Leone A. Treatment of major depression with transcranial direct current stimulation. Bipolar Disord 2006, 8(2):203-204. 10.1111/j.1399-5618.2006.00291.x, 16542193.
36. Lang N, Nitsche MA, Paulus W, Rothwell JC, Lemon RN. Effects of transcranial direct current stimulation over the human motor cortex on corticospinal and transcallosal excitability. Exp Brain Res 2004, 156(4):439-443. 10.1007/s00221-003-1800-2, 14745467.
37. Nitsche MA, Liebetanz D, Lang N, Antal A, Tergau F, Paulus W. Safety criteria for transcranial direct current stimulation (tDCS) in humans. Clin Neurophysiol 2003, 114(11):2220-2222. author reply 2222-3, 10.1016/S1388-2457(03)00235-9, 14580622.
38. Nitsche MA, Boggio PS, Fregni F, Pascual-Leone A. Treatment of depression with transcranial direct current stimulation (tDCS): a review. Exp Neurol 2009, 219(1):14-19. 10.1016/j.expneurol.2009.03.038, 19348793.
39. Poreisz C, Boros K, Antal A, Paulus W. Safety aspects of transcranial direct current stimulation concerning healthy subjects and patients. Brain Res Bull 2007, 72(4-6):208-214.
40. Raimundo RJ, Uribe CE, Brasil-Neto JP. Lack of clinically detectable acute changes on autonomic or thermoregulatory functions in healthy subjects after transcranial direct current stimulation (tDCS). Brain Stimul 2012, 5(3):196-200. 10.1016/j.brs.2011.03.009, 22037121.
41. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl 20):22-33.
42. Ellish NJ, Saboda K, O'Connor J, Nasca PC, Stanek EJ, Boyle C. A prospective study of early pregnancy loss. Hum Reprod 1996, 11(2):406-412. 10.1093/HUMREP/11.2.406, 8671233.
43. Kelly RH, Russo J, Holt VL, Danielsen BH, Zatzick DF, Walker E, Katon W. Psychiatric and substance use disorders as risk factors for low birth weight and preterm delivery. Obstet Gynecol 2002, 100(2):297-304. 10.1016/S0029-7844(02)02014-8, 12151153.
44. Patel SR, Wisner KL. Decision making for depression treatment during pregnancy and the postpartum period. Depress Anxiety 2011, 28(7):589-595. 10.1002/da.20844, 3128653, 21681871.
45. Blumberger DM, Tran LC, Fitzgerald PB, Hoy KE, Daskalakis ZJ. A randomized double-blind sham-controlled study of transcranial direct current stimulation for treatment-resistant major depression. Front Psychiatry 2012, 3:74. 3421236, 22912618.
46. Brunoni AR, Valiengo L, Baccaro A, Zanao TA, de Oliveira JF, Vieira GP, Bueno VF, Goulart AC, Boggio PS, Lotufo PA, Bensenor IM, Fregni F. Sertraline vs. ELectrical Current Therapy for Treating Depression Clinical Trial-SELECT TDCS: design, rationale and objectives. Contemp Clin Trials 2011, 32(1):90-98. 10.1016/j.cct.2010.09.007, 20854930.
47. Brunoni AR, Vanderhasselt MA, Boggio PS, Fregni F, Dantas EM, Mill JG, Lotufo PA, Benseñor IM. Polarity- and valence-dependent effects of prefrontal transcranial direct current stimulation on heart rate variability and salivary cortisol. Psychoneuroendocrinology 2013, 38(1):58-66. 10.1016/j.psyneuen.2012.04.020, 22626867.
48. Herwig U, Padberg F, Unger J, Spitzer M, Schönfeldt-Lecuona C. Transcranial magnetic stimulation in therapy studies: examination of the reliability of 'standard' coil positioning by neuronavigation. Biol Psychiatry 2001, 50(1):58-61. 10.1016/S0006-3223(01)01153-2, 11457424.
49. Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 2002, 47(2):174-180.
50. Demissie K, Joseph KS, Dzakpasu S. Perinatal Health Indicators for Canada: A Resource Manual 2000, Ottawa, ON: Health Canada.
51. Bates JE, Freeland CA, Lounsbury ML. Measurement of infant difficultness. Child Dev 1979, 50(3):794-803. 10.2307/1128946, 498854.
52. Bricker D, Squires J. Ages and Stages Questionnaire 2010, Baltimore, MD: Brookes Publishing, 3.
53. Schonhaut L, Armijo I, Schönstedt M, Alvarez J, Cordero M. Validity of the ages and stages questionnaires in term and preterm infants. Pediatrics 2013, 131(5):e1468-e1474. 10.1542/peds.2012-3313, 23629619.
54. Hermens ML, Adèr HJ, van Hout HP, Terluin B, van Dyck R, de Haan M. Administering the MADRS by telephone or face-to-face: a validity study. Ann Gen Psychiatry 2006, 5:3. 10.1186/1744-859X-5-3, 1435896, 16553958.
55. Kjaergaard M, Arfwedson Wang CE, Waterloo K, Jorde R. A study of the psychometric properties of the Beck depression Inventory-II, the montgomery and Asberg depression rating scale, and the hospital anxiety and depression scale in a sample from a healthy population. Scand J Psychol 2014, 55(1):83-89. 10.1111/sjop.12090, 24256317.
56. Gibson J, McKenzie-McHarg K, Shakespeare J, Price J, Gray R. A systematic review of studies validating the Edinburgh Postnatal Depression Scale in antepartum and postpartum women. Acta Psychiatr Scand 2009, 119(5):350-364. 10.1111/j.1600-0447.2009.01363.x, 19298573.
57. Boyd RC, Le HN, Somberg R. Review of screening instruments for postpartum depression. Arch Womens Ment Health 2005, 8(3):141-153. 10.1007/s00737-005-0096-6, 16133785.
58. Eberhard-Gran M, Eskild A, Tambs K, Opjordsmoen S, Samuelsen SO. Review of validation studies of the Edinburgh postnatal depression scale. Acta Psychiatr Scand 2001, 104(4):243-249. 10.1034/j.1600-0447.2001.00187.x, 11722298.
59. DiPietro JA, Ghera MM, Costigan K, Hawkins M. Measuring the ups and downs of pregnancy stress. J Psychosom Obstet Gynaecol 2004, 25(3-4):189-201.
60. Dennis CL, Coghlan M, Vigod S. Can we identify mothers at-risk for postpartum anxiety in the immediate postpartum period using the State-Trait Anxiety Inventory?. J Affect Disord 2013, 150:1217-1220. 10.1016/j.jad.2013.05.049, 23764383.
61. Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health 2008, 31(2):180-191. 10.1002/nur.20247, 18183564.
62. Walton GD, Ross LE, Stewart DE, Grigoriadis S, Dennis CL, Vigod S. Decisional conflict among women considering antidepressant medication use in pregnancy. Arch Womens Ment Health 2014, doi:10.1007/s00737-014-0448-1.
63. Dowswell T, Bedwell C, Lavender T, Neilson JP. Transcutaneous electrical nerve stimulation (TENS) for pain relief in labour. Cochrane Database Syst Rev 2009, 2:CD007214.